SQZ Biotechnologies Announces First Autoimmune Disorder Sign for Tolerizing Antigen Carrier (TAC) System

Tom Smith

WATERTOWN, Mass.–(Organization WIRE)–SQZ Biotechnologies (NYSE: SQZ), concentrated on unlocking the full opportunity of mobile therapies for multiple therapeutic places, nowadays announced that the 1st scientific translation of the company’s Tolerizing Antigen Provider (TAC) platform in autoimmune disorders will be for celiac disorder, a long-term autoimmune condition that afflicts thousands and […]

WATERTOWN, Mass.–(Organization WIRE)–SQZ Biotechnologies (NYSE: SQZ), concentrated on unlocking the full opportunity of mobile therapies for multiple therapeutic places, nowadays announced that the 1st scientific translation of the company’s Tolerizing Antigen Provider (TAC) platform in autoimmune disorders will be for celiac disorder, a long-term autoimmune condition that afflicts thousands and thousands of individuals and has no accredited drug therapy. The business anticipates an IND filing in the third quarter of 2022. In preclinical types, SQZ™ TACs have demonstrated the ability to induce multi-mechanism antigen-particular tolerance suitable to lots of immune mediated issues. The company’s celiac sickness software may perhaps aid expansion into further autoimmune disorders.

There is sizeable unmet want for patients with celiac condition. Its acute signs and symptoms, likely for prolonged-expression issues, and requirement for a rigorous gluten free food plan can all be extremely tricky,” claimed Armon Sharei, Ph.D., Chief Government Officer at SQZ Biotechnologies. “We are thrilled to use our TAC platform’s wide likely in immune tolerance, coupled with our current fast red blood mobile-primarily based producing capabilities, to make a therapeutic that could deliver a meaningful advantage to patients with celiac ailment. In addition to our current oncology medical trials, implementation of our initial immune tolerance medical software will be an important step to expanding our likely to effects affected person lives.”

SQZ TACs leverage the body’s organic mechanisms of pink blood cell (RBC) clearance and antigen presentation to induce immune tolerance. TACs are derived from affected individual RBCs and are developed to have disease-specific antigen cargos to specialized immune cells that are able of inducing tolerance by a number of mechanisms.

Previously this 12 months, the company presented preclinical findings at the Antigen-Unique Immune Tolerance Digital Summit and the Federation of Clinical Immunology Societies demonstrating that its engineered TACs can generate antigen-unique immune tolerance in intricate designs of autoimmune disorder. SQZ TACs were demonstrated to delete antigen-particular T cells, without causing wide immune suppression. Importantly, SQZ TACs also increased antigen-unique regulatory T cells (Tregs) that exerted strong bystander suppression, exhibiting the skill to suppress pathogenic T cells with unique autoantigen specificities.

Our preclinical investigation has identified that SQZ TACs can leverage physiological processes to induce T cell tolerance to sickness-driving antigens via many mechanisms,” explained Howard Bernstein, M.D., Ph.D., Chief Scientific Officer at SQZ Biotechnologies. “We search ahead to advancing this promising immune tolerance system into the clinic for the therapy of celiac sickness although in parallel continuing preclinical progress for more autoimmune indications, this sort of as Form 1 diabetes.”

The enterprise will leverage its speedy production technique for the improvement of SQZ TACs. Before this calendar year, the business presented scientific demo conclusions at the American Society of Scientific Oncology demonstrating the medical feasibility of its manufacturing method. In the Phase 1 trial of the company’s APC therapeutic applicant for HPV optimistic tumors, client batches of the investigational cell treatment were being manufactured in significantly less than 24 several hours. The adaptability and scalability of the company’s manufacturing process enables it to be used for each the TAC and Oncology platforms irrespective of diverse mobile forms and antigen cargos. SQZ TAC therapeutic candidates are also expected to be suitable with prospective long run level of treatment implementations.

About Celiac Illness

Celiac sickness is a serious autoimmune ailment that occurs in genetically predisposed persons.1 2 The disease is brought on by consuming foods that contains gluten, which is located in wheat, barley, and rye. Illness signs can involve abdominal pain, diarrhea, nausea, vomiting, and other widespread signs. When gluten is ingested the body mounts an immune response that assaults and damages the villi that line the tiny intestine, which can effect nutrient absorption.3 Many people today who have celiac sickness have not been diagnosed,4 having said that inhabitants-primarily based studies suggest that the illness influences about 2 million people in the United States and about 1% of the inhabitants all over the world, with regional distinctions.5 6 There is currently no approved drug cure and sufferers need to consequently manage a gluten-no cost eating plan, which entails strict, lifelong avoidance of exposure to gluten proteins. Extended-expression troubles of celiac disorder may well include malnutrition, accelerated osteoporosis, nervous process problems and issues similar to copy. Exceptional complications can include most cancers of the compact intestine, cirrhosis, and non-Hodgkin lymphoma.

About SQZ TACs

SQZ TACs are a purple blood cell-derived mobile treatment platform remaining designed as an antigen-particular immune tolerance solution for autoimmune conditions. The system is built to leverage the organic approach of RBC clearance by qualified antigen presenting cells (APCs) in the lymphoid organs. This physiological mechanism is tolerogenic by default, instructing the immune system not to mount an assault. SQZ TACs are produced by squeezing RBCs with sickness-particular antigens and are produced to surface aged. SQZ TACs are made to be quickly engulfed by skilled APCs and to act as a “Trojan horse” to present antigens in a non-inflammatory context, inducing tolerization of the patient’s T cells from the distinct target. Preclinical facts has demonstrated deletion and anergy of antigen-specific T cells as nicely as induction of disorder certain Tregs capable of bystander suppression.

About SQZ Biotechnologies

SQZ Biotechnologies Business is a clinical-stage biotechnology company focused on unlocking the entire possible of cell therapies for clients close to the environment and has energetic packages in Oncology, Autoimmune and Infectious Conditions, as nicely as further exploratory initiatives to aid long term pipeline progress. The company’s proprietary Mobile Squeeze® technologies features the special capacity to produce numerous organic supplies into numerous mobile types to engineer what we believe can be a broad variety of potential therapeutics. With demonstrated production timelines less than 24 hours and the possibility to reduce preconditioning and prolonged clinic stays, our tactic could noticeably broaden the therapeutic array and accessibility of cell therapies. The company’s to start with therapeutic applications seek out to create goal-unique immune responses, both in activation for the procedure of strong tumors and infectious illnesses, and in immune tolerance for the procedure of unwelcome immune reactions and autoimmune health conditions. For much more information and facts, remember to visit www.sqzbiotech.com.

Ahead Hunting Statements

This push release is made up of ahead-wanting statements inside the this means of the Non-public Securities Litigation Reform Act of 1995. All statements contained that do not relate to issues of historical truth must be viewed as ahead-searching statements, which include devoid of limitation statements relating to our platform improvement, producing capabilities, product or service candidates, preclinical and scientific things to do and results, advancement plans and development, clinical efficacy, regulatory submissions, therapeutic affect and industry alternatives. These forward-on the lookout statements are based mostly on management’s recent anticipations. Precise effects could differ from people projected in any ahead-hunting statements thanks to various chance elements. These components consist of, among the many others, threats and uncertainties associated to our restricted working record our major losses incurred considering that inception and expectation to incur considerable additional losses for the foreseeable future the enhancement of our initial products candidates, upon which our company is highly dependent the impression of the COVID-19 pandemic on our functions and clinical pursuits our want for further funding and our cash runway the prolonged, costly, and unsure method of clinical drug progress, like unsure results of medical trials and prospective delays in regulatory acceptance our means to preserve our interactions with our third bash suppliers and protection of our proprietary technology, mental house portfolio and the confidentiality of our trade strategies. These and other significant components reviewed underneath the caption “Threat Components” in our Yearly Report on Kind 10-K and other filings with the U.S. Securities and Trade Commission could induce precise success to vary materially from individuals indicated by the ahead-looking statements. Any forward-seeking statements depict management’s estimates as of this date and SQZ undertakes no obligation to update these ahead-on the lookout statements, irrespective of whether as a final result of new data, the event of present activities, or or else, until needed by legislation.

Specified information and facts contained in this push release relates to or is primarily based on studies, publications, surveys and other facts acquired from 3rd-party resources and our possess inside estimates and study. Although we believe that these 3rd-bash resources to be responsible as of the date of this press launch, we have not independently verified, and we make no illustration as to the adequacy, fairness, accuracy or completeness of any information received from third-get together resources.


1 Leonard MM, Sapone A, Catassi C, et al. Celiac Ailment and Nonceliac Gluten Sensitivity: A Review. JAMA 2017318:647-656

2 Celiac Sickness Foundation web-site (as of Sept 13,2021)

3 Over and above Celiac site (as of Sept 13, 2021)

4 Countrywide Institute of Diabetic issues and Digestive and Kidney Illnesses web site (as of Sept 13, 2021)

5 Lionetti E, Gatti S, Pulvirenti A, et al. Celiac ailment from a world wide point of view. Ideal Pract Res Clin Gastroenterol 201529:365-79.

6 Leonard MM, Sapone A, Catassi C, et al. Celiac Condition and Nonceliac Gluten Sensitivity: A Review. JAMA 2017318:647-656

Next Post

How to Locate Cost savings and A lot more

If you’re wanting at treatment method options for rheumatoid arthritis (RA), you might want to find out additional about leflunomide (Arava). Leflunomide is a generic prescription drug that is used to treat RA in older people. It will come as a tablet which is taken by mouth. Leflunomide belongs to […]

Subscribe US Now